轻度缺血性卒中症状患者结局预测因素:MaRISS研究
MaRISS是一项前瞻性观察研究,纳入1765例症状发作4.5小时内、基线NIHSS 0-5分的缺血性卒中或TIA患者,评估90天多维结局并分析阿替普酶效应。结果显示37%患者90天存在残疾,未发现阿替普酶对主要结局的整体效应,但在NIHSS 3-5亚组中提示有效。
要点
- 低NIHSS卒中患者中37%在90天存在残疾,25%未独立。
- 年龄、女性、少数族裔、糖尿病、房颤等是更差结局的预测因素。
- 阿替普酶整体未显示对主要结局的效应,NIHSS 3-5亚组提示有效。
核心结论
- 大部分低NIHSS卒中患者90天结局为残疾,基线预测因素包括年龄、性别、种族、合并症及神经体征。
- 阿替普酶对整体队列主要结局未显示效应,但在NIHSS 3-5亚组中提示有效。
研究设计与样本
- 前瞻性观察研究,纳入1765例缺血性卒中或TIA患者,基线NIHSS 0-5分,症状发作4.5小时内,来自100家Get With The Guidelines-Stroke参与医院。
主要发现
- 90天时37%患者残疾,25%未独立。
- 更差结局见于老年人、女性、非西班牙裔黑人和西班牙裔、医疗补助接受者、吸烟者、糖尿病、房颤、既往卒中、更高基线NIHSS、视野缺损和肢体无力患者。
- 阿替普酶治疗组与未治疗组结局相似;治疗组更年轻(64±13 vs 67±1.4)且NIHSS更高(2.9±1.4 vs 1.7±1.4)。
- 调整年龄、性别、种族和基线NIHSS后,阿替普酶对主要结局无效应,但在基线NIHSS 3-5亚组中与Stroke Impact Scale-16相关。
- 症状性颅内出血记录<1%。
关键数值与推荐
- 主要结局为90天改良Rankin量表评分0-1;次要结局包括Barthel指数、Stroke Impact Scale-16和欧洲生活质量的良好结局。
临床怎么用
- 对低NIHSS卒中患者应识别残疾预测因素并进行多维结局评估。
- 阿替普酶在整体低NIHSS人群中的获益未证实,NIHSS 3-5患者可能获益需进一步研究。
局限性
- 观察性设计,阿替普酶治疗非随机,存在选择偏倚。
- 亚组分析样本受限,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Although most strokes present with mild symptoms, these have been poorly represented in clinical trials. The objective of this study is to describe multidimensional outcomes, identify predictors of worse outcomes, and explore the effect of thrombolysis in this population. METHODS: This prospective observational study included patients with ischemic stroke or transient ischemic attack, a baseline National Institutes of Health Stroke Scale (NIHSS) score 0 to 5, presenting within 4.5 hours from symptom onset. The primary outcome was a 90-day modified Rankin Scale score of 0 to 1; secondary outcomes included good outcomes in the Barthel Index, Stroke Impact Scale-16, and European Quality of Life. Multivariable models were created to determine predictors of outcomes and the effect of alteplase. RESULTS: A total of 1765 participants were included from 100 Get With The Guidelines-Stroke participating hospitals (age, 65±14; 42% women; final diagnosis of ischemic stroke, 90%; transient ischemic attack, 10%; 57% received alteplase). At 90 days, 37% were disabled and 25% not independent. Worse outcomes were noted for older individuals, women, non-Hispanic Blacks and Hispanics, Medicaid recipients, smokers, those with diabetes, atrial fibrillation, prior stroke, higher baseline NIHSS, visual field defects, and extremity weakness. Similar outcomes were noted for the alteplase-treated and untreated groups. Alteplase-treated patients were younger (64±13 versus 67±1.4) with higher NIHSS (2.9±1.4 versus 1.7±1.4). After adjusting for age, sex, race/ethnicity, and baseline NIHSS, we did not identify an effect of alteplase on the primary outcome but did find an association with Stroke Impact Scale-16 in the restricted sample of baseline NIHSS score 3–5. Few symptomatic intracerebral hemorrhages were recorded (<1%). CONCLUSIONS: A large proportion of stroke patients presenting with low NIHSS have a disabled outcome. Baseline predictors of worse outcomes are described. An effect of alteplase on outcomes was not identified in the overall cohort, but a suggestion of efficacy was noted in the NIHSS 3–5 subgroup. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02072681.
引用
- Romano JG, Gardener H, Campo-Bustillo I, et al. Predictors of Outcomes in Patients With Mild Ischemic Stroke Symptoms: MaRISS. Stroke. 2021. PMID: 33947209. doi:10.1161/STROKEAHA.120.032809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。